Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?

Authors :: Giustino Parruti
C.F. Perno
Francesca Ceccherini-Silberstein
Fabio Continenza
M. Puoti
V.C. Di Maio
S. Bruno
Cesare Sarrecchia
Carlo Magni
Daniele Armenia
J. Vecchiet
Mario Angelico
L. Carioti
Giuliano Rizzardini
D. Di Paolo
F. De Luca
Sergio Babudieri
Ilaria Lenci
F. De Leonardis
M. Andreoni
Marianna Aragri
M. Tontodonati
Valeria Micheli
A. De Maria
Antonio Picciotto
Maria Concetta Bellocchi
Maria Stella Mura
Valeria Cento
Ennio Polilli
Lorenzo Nosotti
Simona Francioso
Aldo Bertoli
F.P. Antonucci
A. Manunta
Source :: Digestive and Liver Disease. 46:e47-e48
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: Standard Population
Hepatology
business.industry
Gastroenterology
Ultra deep sequencing
Virology
Telaprevir
chemistry.chemical_compound
chemistry
Boceprevir
Added value
medicine
business
medicine.drug

Full Text Access

Tools